Malignant transformation of mastocytoma developed on skin mastocytosis into cutaneous mast cell sarcoma

American Journal of Surgical Pathology

Volumn 36, Issue 5, 2012, Pages 779-782

  Auquit Auckbur, Isabelle ^a   Lazar, Cĝlin ^a,b   Deneuve, Sophie ^b   Guillemet, Cécile ^b   Cordel, Nadège ^a   Blanchard, France ^c   Joly, Pascal ^b,d   Courville, Philippe ^c  

^a Departments of Plastic Surgery   (France)

^b ROUEN UNIVERSITY HOSPITAL   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d Centre Hospitalier Universitaire Pointe a Pitre   (Guadeloupe)

Author keywords

c Kit; CD117; imatinib; mast cell sarcoma; mastocytosis; radiotherapy; surgery

Indexed keywords

ADULT; ARTICLE; CASE REPORT; CELL TRANSFORMATION; FATALITY; HUMAN; MALE; MASTOCYTOMA; PATHOLOGY; SARCOMA; SKIN TUMOR;

ADULT; CELL TRANSFORMATION, NEOPLASTIC; FATAL OUTCOME; HUMANS; MALE; MAST-CELL SARCOMA; MASTOCYTOMA, SKIN; SKIN NEOPLASMS;

EID: 84859895288     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e31824c0d92     Document Type: Article

References (22)

1. Akin C. Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on molecular pathology. J Mol Diagn. 2006; 8: 412-419. (Pubitemid 44377921)
2. Antonescu CR. Targeted therapy of cancer: new roles for pathologists in identifying GISTs and other sarcomas. Mod Pathol. 2008; 21(suppl 2): S31-S36. (Pubitemid 351592776)
3. Ashinoff R, Soter NA, Freedberg IM. Solitary mastocytoma in adults. Treatment by excision. J Dermatol Surg Oncol. 1993; 19: 487-488. (Pubitemid 24173966)
4. Azañ a JM, Torrelo A, Mediero IG, et al. Urticaria pigmentosa: a review of 67 pediatric cases. Pediatr Dermatol. 1994; 11: 102-106. (Pubitemid 24174274)
5. Brcić L, Vuletić LB, Stepan J, et al. Mast-cell sarcoma of the tibia. J Clin Pathol. 2007; 60: 424-425. (Pubitemid 46596565)
6. Chott A, Guenther P, Huebner A, et al. Morphologic and immunophenotypic properties of neoplastic cells in a case of mast cell sarcoma. Am J Surg Pathol. 2003; 27: 1013-1019. (Pubitemid 36758906)
7. Debiec-Rychter M, Dumez H, Judson I, et al. Use of c-KIT/ PDGFRA mutations analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumors entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2004; 40: 689-695. (Pubitemid 38326618)
8. Dirnhofer S, Zimpfer A, Went P. The diagnostic and predictive role of kit (CD117). Ther Umsch. 2006; 63: 273-278.
9. González I, Andreu EJ, Panizo A, et al. Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis. Clin Cancer Res. 2004; 10: 751-761. (Pubitemid 38174013)
10. Gronchi A, Blay JY, Trent JC. The role of high-dose imatinib in the management of patients with gastrointestinal stromal tumor. Cancer. 2010; 116: 1847-1858.
11. Guenther PP, Huebner A, Sobottka SB, et al. Temporary response of localized intracranial mast cell sarcoma to combination chemotherapy. J Pediatr Hematol Oncol. 2001; 23: 134-138. (Pubitemid 32162678)
12. Horny HP, Parwaresch MR, Kaiserling E, et al. Mast cell sarcoma of the larynx. J Clin Pathol. 1986; 39: 596-602. (Pubitemid 16069663)
13. Kettelhut BV, Metcalfe DD. Pediatric mastocytosis. Ann Allergy. 1994; 73: 197-202.
14. Kojima M, Nakamura S, Itoh H, et al. Mast cell sarcoma with tissue eosinophilia arising in the ascending colon. Mod Pathol. 1999; 12: 739-743. (Pubitemid 29354889)
15. Krauth MT, Födinger M, Rebuzzi L, et al. Aggressive systemic mastocytosis with sarcoma-like growth in the skeleton, leukemic progression, and partial loss of mast cell differentiation antigens. Haematologica. 2007; 92: e126-e129.
16. Sotlar K, Horny HP, Lebherz J, et al. Association of bone marrow mastocytosis with extremely immature extramedullary mast cell sarcoma. Pathologe. 1997; 18: 252-256. (Pubitemid 27267285)
17. Terheyden P, Houben R, Pajouh P, et al. Response to imatinib mesylate depends on the presence of the V559A-mutated KIT oncogene. J Invest Dermatol. 2010; 130: 314-316.
18. Uziel O, Fenig E, Nordenberg J, et al. Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines. Br J Cancer. 2005; 92: 1881-1891. (Pubitemid 40826137)
19. Valent P, Akin C, Sperr WR, et al. Mastocytosis: pathology, genetics, and current options for therapy. Leuk Lymphoma. 2005; 46: 35-48.
20. Valent P, Ghannadan M, Akin C, et al. On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts. Eur J Clin Invest. 2004; 34(suppl 2): S41-S52.
21. Valent P, Horny HP, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res. 2001; 25: 603-625. (Pubitemid 32506768)
22. Zermati Y, De Sepulveda P, Féger F, et al. Effects of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-Kit receptors found in mast cells neoplasms. Oncogene. 2003; 22: 660-664. (Pubitemid 36269279)